Effect of RA-233 on erythrocytes from patients with eczema.
Erythrocytes (RBCs) from patients with eczema are less flexible than erythrocytes obtained from normal healthy individuals. The addition of RA-233 (a membrane-active agent which is a phosphodiestrase inhibitor) improved the deformability of these rigid RBCs, and this improvement was found to be statistically significant at p less than 0.0001. The increase in deformability that was observed after the addition of the drug is assumed to be related to the increases in intracellular Ca2+,K+ and blood ATP levels which are brought about by the action of this drug.
Meky
N
N
Faculty of Science, Ain Shams University, Cairo, Egypt.
D000255:Adenosine Triphosphate / Q000097:blood; D002118:Calcium / Q000097:blood; D004485:Eczema / Q000097:blood*; D004907:Erythrocyte Deformability / Q000187:drug effects*; D006801:Humans; D009012:Mopidamol / Q000494:pharmacology*; D011188:Potassium / Q000097:blood; D011743:Pyrimidines / Q000494:pharmacology*
D011743:Pyrimidines; D009012:Mopidamol; D000255:Adenosine Triphosphate; D011188:Potassium; D002118:Calcium